Ignyta Inc

163 articles with Ignyta Inc

• Mainstay Medical Announces the Appointment of Matthew Onaitis as Chief Financial Officer

  8/20/2018

  Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces the appointment of Matthew Onaitis as Chief Financial Officer, effective August 20, 2018.

• 

  Rare Cancer Challenge: Genomic Screening and Clinical Trials

  7/5/2018

  Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.

• Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor

  12/29/2017

  The company intends to initiate the TITAN study, a first-in-human study of RXDX-106 in patients with locally advanced or metastatic solid tumors.

• 

  Roche Does Last-Minute Christmas Shopping, Drops $1.7 Billion on San Diego Biotech

  12/22/2017

  Roche got in some last-minute Christmas shopping, shelling out $1.7B for San Diego's Ignyta.

• Ignyta Reports Granting of Inducement Awards - Nov. 16, 2017

  11/16/2017

  The awards were made on November 15, 2017, under Ignyta’s 2017 Employment Inducement Equity Incentive Award Plan.

• Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results

  11/8/2017

  For the third quarter of 2017, net loss was $28.6 million, or $0.51 per share, compared with $23.3 million, or $0.56 per share, for the third quarter of 2016.

• Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) Meeting

  11/8/2017

  Ignyta today announced new preclinical data for RXDX-106 - a novel immunomodulatory agent that demonstrated potent anti-tumor activity, alone and in combination with checkpoint inhibitors, by modulating the tumor microenvironment (TME) through TYRO3, AXL, and MER (TAM) receptor tyrosine kinase (RTK) inhibition.

• Ignyta Announces Pricing of Public Offering of Common Stock of 10 Million Share

  10/20/2017

  Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of 10.0 million shares of its common stock at a price to the public of $16.00 per share.

• Ignyta Announces Proposed Public Offering Of Common Stock Of $125,000,000

  10/19/2017

  Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock.

• 

  Ignyta Stock Booms on Promising Mid-Stage Lung Cancer Data

  10/18/2017

  The good news led Ignyta's stock to jump about five percent before settling down.

• Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors

  10/17/2017

  Ignyta, Inc. today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation for entrectinib in the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapy.

• Ignyta Issued Four Inducement Awards

  10/16/2017

  Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, announced today that it has issued four inducement awards to new non-executive employees.

• Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting

  10/3/2017

• Ignyta Announces Updated Data On Entrectinib In ROS1 NSCLC To Be Presented At The IASLC 18th World Conference On Lung Cancer

  9/28/2017

• Ignyta Reports Granting Of Inducement Awards

  9/18/2017

• Ignyta Provides Update On Entrectinib And RXDX-105 At The ESMO 2017 Congress

  9/11/2017

• Ignyta Announces Presentation Of New Phase IB Clinical Data On RXDX-105 In RET Fusion-Positive NSCLC At ESMO 2017 Congress

  9/8/2017

• Ignyta Provides Regulatory Update On Entrectinib ROS1 Lung Cancer Development Program

  9/6/2017

• Ignyta To Host Conference Call And Webcast On Entrectinib ROS1 Lung Cancer Update On September 6, 2017

  8/31/2017

• Ignyta Announces Second Quarter 2017 Company Highlights And Financial Results

  8/9/2017